Personalized Pharmacotherapy in Obesity: Current Challenges, Emerging Therapeutic Algorithms, and Future Directions

Kruthika T*

Department of Pharmacy Practice, Krupanidhi College Of Pharmacy, Carmelaram – 560035,

Karnataka, India.

 

Correspondence: kruthikareddy126@gmail.com

DOI: https://doi.org/10.71431/IJRPAS.2026.5803      

Article Information		Abstract
Research Article Received: 18/08/2026 Accepted: 02/09/2026 Published:04/09/2026   Keywords   Obesity; Personalized pharmacotherapy; Precision medicine; Anti-obesity medications; GLP-1 receptor agonists; Pharmacogenomics; Therapeutic algorithms; Precision obesity medicine.		Obesity is a chronic, relapsing disease driven by multiple factors and stands as a major contributor to global morbidity and mortality. Its development involves an intricate interplay among genetic, epigenetic, metabolic, hormonal, environmental, and behavioral influences, causing wide variation in how patients present and respond to treatment. While lifestyle changes remain central to managing obesity, pharmacotherapy is now a core part of care for patients who cannot achieve or maintain meaningful weight loss through behavioral modifications alone. Yet standard drug approaches often rely on generalized strategies that overlook significant differences between individuals in drug efficacy, safety, tolerability, and long-term adherence. Recent progress in precision medicine has moved the field toward personalized pharmacotherapy, tailoring treatment choices to patient-specific traits such as obesity phenotype, metabolic profile, genetic background, co-occurring conditions, treatment goals, and personal preferences. The arrival of incretin-based therapies—specifically glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists—has greatly improved clinical outcomes, delivering deeper and more sustained weight loss alongside better control of obesity-related heart and metabolic complications. Beyond these drugs, progress in pharmacogenomics, biomarker discovery, digital health tools, artificial intelligence, and multimodal care models promises to refine individualized obesity management even further. This review explores the changing landscape of personalized obesity pharmacotherapy by looking at the scientific basis for precision treatment, currently available anti-obesity medications, patient phenotyping methods, pharmacogenomic tools, and emerging care algorithms. It also addresses practical hurdles such as variable treatment response, limited biomarker validation, access, cost, and long-term adherence, while pointing out future directions to help move care away from simple weight-focused management and toward tailored, mechanism-based approaches. Bringing precision medicine into everyday clinical practice can help optimize results, reduce side effects, and improve long-term disease management for people living with obesity.

 

INTRODUCTION

Obesity is a chronic, progressive, and relapsing disease characterized by excessive or abnormal accumulation of adipose tissue that impairs health and significantly increases the risk of premature morbidity and mortality. Beyond its traditional classification based on body mass index (BMI), obesity is now recognized as a complex biological disorder involving dysregulation of energy homeostasis, neuroendocrine signaling, adipose tissue function, immune responses, and metabolic pathways. This evolving understanding has shifted the perception of obesity from a lifestyle-related condition to a multifactorial chronic disease requiring long-term, individualized management strategies.[1,2]

The prevalence of obesity has increased dramatically over the past several decades, making it one of the most pressing public health challenges worldwide. According to recent global estimates, more than one billion individuals are living with obesity, and its prevalence continues to rise across all age groups and socioeconomic settings. Obesity substantially increases the risk of developing type 2 diabetes mellitus, hypertension, dyslipidemia, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnea, chronic kidney disease, osteoarthritis, infertility, and several obesity-associated malignancies. Collectively, these complications contribute to reduced quality of life, increased healthcare utilization, and considerable economic burden on healthcare systems.[3,4]

Although lifestyle modification, including dietary intervention, physical activity, and behavioral therapy, remains the cornerstone of obesity management, long-term weight maintenance through lifestyle measures alone is frequently unsuccessful. Physiological adaptations following weight loss, such as increased appetite, reduced resting energy expenditure, alterations in gut hormone secretion, and activation of central appetite-regulating pathways, promote weight regain and limit sustained therapeutic success. Consequently, obesity should be managed as a chronic disease requiring long-term treatment rather than a condition addressed solely through short-term weight reduction efforts.[5]

Pharmacotherapy has emerged as an essential component of comprehensive obesity management for individuals who fail to achieve adequate weight reduction through lifestyle intervention alone or who present with obesity-related comorbidities. Over the past decade, the therapeutic landscape has evolved considerably with the introduction of incretin-based agents, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, which have demonstrated unprecedented efficacy in achieving clinically meaningful and sustained weight loss while improving glycemic control and cardiometabolic outcomes. These advances have transformed expectations regarding the role of anti-obesity medications and have narrowed the therapeutic gap between pharmacological treatment and bariatric surgery in selected patient populations.[6_8]

Despite these advances, treatment responses vary considerably. Patients taking the same medication often experience marked differences in weight reduction, metabolic improvement, side effect profiles, and adherence. This variability reflects a complex mix of genetic predisposition, metabolic phenotype, hormonal regulation, gut microbiota, behavioral factors, psychological traits, concomitant illnesses, and environmental influences. Such diversity highlights the shortcomings of conventional treatment algorithms that rely primarily on body mass index thresholds while overlooking individual biological differences.[9]

Precision medicine offers a promising way to address these limitations by incorporating patient-specific clinical, molecular, genetic, and metabolic details into medical decisions. Rather than applying a uniform treatment, personalized pharmacotherapy aims to match the right drug to the right patient at the right time. Factors that can guide individual treatment selection include obesity phenotype, eating behavior patterns, insulin resistance, fat tissue distribution, related health complications, pharmacogenomic traits, patient preferences, and treatment goals. Although several components of precision obesity care are still under investigation, progress in biomarker discovery, multi-omics technologies, and computational analytics is rapidly expanding opportunities for individualized care.[10,11]

In parallel, development has accelerated for next-generation anti-obesity drugs targeting multiple neurohormonal pathways. Triple agonists, amylin analogs, combination therapies, and novel gut hormone modulators are currently being evaluated with the goal of achieving greater effectiveness while minimizing adverse effects. At the same time, artificial intelligence, digital therapeutics, continuous metabolic monitoring, and predictive clinical algorithms are increasingly explored to optimize patient selection, improve adherence, and support real-time medical decision-making. Together, these innovations are set to redefine obesity care by moving beyond simple weight-centric approaches toward mechanism-based, individualized treatment.[12,13]

Given the rapid evolution of obesity pharmacotherapy and the growing emphasis on precision medicine, a comprehensive synthesis of current evidence is warranted. This review examines the scientific rationale for personalized pharmacotherapy in obesity, evaluates currently approved and emerging anti-obesity drugs, discusses patient phenotyping and pharmacogenomic approaches, and explores evolving therapeutic algorithms that may facilitate individualized treatment. Additionally, current challenges, evidence gaps, and future directions are highlighted to provide a practical perspective on integrating precision pharmacotherapy into routine clinical practice.

LITERATURE SEARCH STRATEGY

A narrative literature search was performed to gather evidence on personalized pharmacotherapy in obesity, covering obesity phenotyping, pharmacological treatment, pharmacogenomics, precision medicine, emerging anti-obesity therapies, digital health, and artificial intelligence. PubMed/MEDLINE, Scopus, and Google Scholar were searched for peer-reviewed publications appearing between January 2000 and August 2026. The search terms combined "obesity," "personalized pharmacotherapy," "precision medicine," "phenotyping," "pharmacogenomics," "anti-obesity medications," "GLP-1 receptor agonists," "GIP/GLP-1 receptor agonists," "digital health," "artificial intelligence," and "predictive analytics." Preference was given to recent systematic reviews, randomized controlled trials, clinical guidelines, consensus statements, pharmacogenomic studies, and major clinical investigations relevant to individualized obesity treatment. Reference lists of key articles were also reviewed to find additional relevant studies. Since this was a narrative review, articles were chosen for their relevance to the review's scope and objectives rather than according to a formal systematic-review or meta-analysis protocol.

BIOLOGICAL BASIS FOR PERSONALIZED PHARMACOTHERAPY IN OBESITY

Obesity is a biologically diverse disease caused by intricate interactions among genetic risk, neuroendocrine control, metabolic shifts, environmental factors, and behavioral habits. Even though excess fat accumulation defines obesity, the driving mechanisms behind how it develops and progresses vary greatly between people. This diversity leads to wide differences in clinical symptoms, related health complications, and how patients respond to therapy, which shows the limits of standardized treatment approaches and supplies the scientific rationale for personalized pharmacotherapy.[14]

Body weight regulation is managed by a complex web of central and peripheral signaling pathways that work to maintain energy balance. In the hypothalamus, nerve cells within the arcuate nucleus process signals from the body about nutritional state, controlling food intake via hunger-stimulating and satiety-promoting pathways. Neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons drive appetite and lower energy expenditure, while proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) neurons enhance fullness and raise energy expenditure. Hormonal signals—such as leptin, insulin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY), cholecystokinin (CCK), ghrelin, and glucose-dependent insulinotropic polypeptide (GIP)—constantly engage with these hypothalamic circuits to govern appetite and metabolic stability. When these pathways are disrupted, it leads to chronic overeating, flawed satiety signaling, and steady weight gain.[15-17]

Figure 1

 

Once viewed merely as passive fat storage, adipose tissue is now understood as a metabolically active endocrine organ that releases a variety of adipokines, cytokines, and inflammatory factors. In obesity, enlarged and dysfunctional fat cells drive chronic low-grade inflammation by stepping up production of tumor necrosis factor-alpha, interleukin-6, monocyte chemoattractant protein-1, and other pro-inflammatory signals. This inflammatory environment promotes insulin resistance, blood vessel dysfunction, abnormal fat processing, and fat buildup in ectopic tissues, raising the risk of heart and metabolic disease. Significantly, people vary widely in how fat is distributed, their level of inflammation, and their degree of metabolic dysfunction, which explains why individuals with identical BMI measurements can have very different metabolic risk profiles.18,19

Genes account for roughly 40% to 70% of individual differences in susceptibility to obesity. While rare single-gene forms stem from pathogenic variants in the leptin-melanocortin pathway, the vast majority of obesity cases are polygenic, driven by numerous common genetic variants with small individual impacts. Genome-wide association studies have located hundreds of susceptibility regions connected to appetite control, fat cell development, insulin signaling, lipid processing, and energy expenditure. Variants in genes like FTO, MC4R, TMEM18, BDNF, and PCSK1 consistently show ties to obesity risk, although their exact influence on drug response remains partly unclear. Emerging evidence indicates that genetic makeup may help account for variations in weight loss success, side effect profiles, and medication adherence, backing the inclusion of pharmacogenomics in future treatment choices.[20,21][

Beyond inherited gene differences, epigenetic changes and environmental factors further add to the biological diversity seen in obesity. DNA modification, histone adjustments, and non-coding RNAs shape the expression of genes linked to fat cell creation, inflammation, insulin sensitivity, and appetite control. These epigenetic processes are dynamic and can shift based on food choices, physical activity, sleep quality, stress exposure, and environmental obesogens. Consequently, individuals with identical genetic profiles can display very different metabolic characteristics, underscoring why both inherited and acquired factors must be weighed when choosing drug treatments.[22]

The gut microbiome has surfaced as another key driver of metabolic health and treatment response. Shifts in microbial balance and makeup are tied to higher gut permeability, chronic inflammation, altered bile acid processing, and changes in short-chain fatty acid production, all of which shape host energy balance. Furthermore, accumulating data suggest that gut flora composition can alter how patients respond to dietary changes and incretin-based drug therapy, pointing to a future where microbiome analysis might guide customized obesity care. Even so, routine clinical application is still restricted by technical variations and a lack of proven predictive markers.[23,24]

Clinical diversity in obesity goes beyond molecular pathways, encompassing distinct metabolic and behavioral phenotypes. Some individuals display primarily hyperphagic eating habits driven by faulty fullness signals, whereas others show emotional eating, altered reward pathways, decreased energy expenditure, or obesity triggered by hormonal conditions or medications. Similarly, metabolically healthy and metabolically unhealthy obesity represent contrasting profiles carrying different risks of heart and metabolic disease despite similar fat mass. Recognizing these distinct phenotypes holds clear therapeutic value, as drug treatments aimed at appetite control, nutrient absorption, or energy expenditure can show differing levels of success depending on the primary underlying mechanism.[25]

Another hurdle in treating obesity is the body's built-in defense against weight loss. Cutting calories or losing weight through drugs triggers adaptive shifts that boost hunger, lower resting metabolism, and promote energy conservation. Hormonal shifts, such as drops in circulating leptin and peptide YY levels paired with higher ghrelin production, encourage weight regain once treatment stops. These counter-regulatory reactions explain why obesity so often relapses, highlighting the necessity of long-term, tailored treatment plans rather than short-term fixes.[26]

Taken together, these biological, genetic, metabolic, and behavioral variations show that obesity is not a single condition but rather a spectrum of linked disorders driven by different underlying pathways. As a result, choosing drug therapy based strictly on BMI or total body weight falls short of capturing the true complexity of the disease. A precision medicine framework that factors in obesity phenotype, metabolic traits, coexisting conditions, genetic background, and patient-centered goals provides a more logical structure for boosting treatment effectiveness while cutting down side effects. As our grasp of obesity biology expands, building molecular and clinical biomarkers into medical decision-making will likely become a foundational element of future obesity care.

CURRENT ANTI-OBESITY PHARMACOTHERAPY: MOVING TOWARD INDIVIDUALIZED TREATMENT SELECTION

Obesity drug treatment has changed substantially over the past decade, shifting from modest appetite suppressants to highly effective therapies that target intricate hormonal pathways governing hunger, fullness, and energy metabolism. Current guidelines advise considering anti-obesity medications alongside comprehensive lifestyle changes for adults with a body mass index of 30 or higher, or 27 and above with weight-related complications, especially when lifestyle adjustments alone fail to produce meaningful and lasting weight loss.[27] Even with multiple options available, picking the right treatment remains difficult because of variations in effectiveness, safety profiles, contraindications, cost, availability, and individual patient traits.

Historically, drug treatment for obesity was held back by limited weight-loss results and safety concerns regarding cardiovascular or psychiatric effects. Older options, such as stimulant-based appetite suppressants and fat-absorption blockers, provided mixed benefits but frequently caused tolerability problems or poor long-term adherence. The arrival of incretin-based drugs has transformed the treatment landscape by delivering much greater weight reduction while addressing several metabolic abnormalities linked to obesity.[28]

Glucagon-like Peptide-1 Receptor Agonists

GLP-1 receptor agonists stand as one of the most significant breakthroughs in obesity pharmacotherapy. GLP-1 is a natural incretin hormone released by intestinal L-cells after eating, where it supports glucose-dependent insulin secretion, slows stomach emptying, suppresses glucagon release, and helps regulate appetite centrally. Drug activation of these receptors enhances fullness, dampens hunger signals, and curtails calorie consumption through actions on hypothalamic and mesolimbic circuits.[29]

Among current GLP-1 receptor agonists, liraglutide and semaglutide have proven highly effective for long-term weight control. Liraglutide at a once-daily 3 mg dose was among the first GLP-1 receptor agonists cleared specifically for obesity care, achieving average weight reductions of roughly 5% to 8% when paired with lifestyle modifications. The SCALE clinical trial series demonstrated that liraglutide improved weight loss outcomes over placebo while also bettering cardiometabolic risk factors like blood sugar levels and blood pressure.[30]

Semaglutide, a once-weekly long-acting GLP-1 receptor agonist, has pushed obesity treatment even further forward. The STEP clinical trial program yielded substantially greater weight loss than previous medications, with average reductions nearing 15% of initial body weight among individuals with obesity but without diabetes when combined with lifestyle interventions. Alongside weight loss, semaglutide reduced waist circumference, enhanced glycemic metrics, lowered inflammatory markers, and improved multiple cardiovascular risk factors.[31]

Even so, responses to GLP-1 receptor agonists vary widely. While some patients achieve significant weight loss, others show limited results despite proper drug exposure and adherence. Factors shaping this response include baseline metabolic phenotype, the degree of insulin resistance, eating habits, genetic differences, digestive tolerance, and how long treatment is maintained. Recognizing these drivers can help clinicians spot patients most likely to succeed with GLP-1 therapy and avoid pushing ineffective dose increases. Frequent side effects involve nausea, vomiting, diarrhea, constipation, and appetite suppression, which typically depend on the dose and subside with gradual titration. Less common but clinically meaningful risks include gallbladder complications alongside potential restrictions for individuals with specific endocrine disorders. Because of this, tailoring therapy to individual tolerance, coexisting health conditions, and patient preference remains vital for successful long-term management.

Dual GIP/GLP-1 Receptor Agonists

The rise of dual incretin receptor agonists represents a major step forward in obesity care by hitting several hormonal systems that control energy balance at the same time. Tirzepatide, which acts on both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, has shown superior weight-loss results compared to earlier medications.

While GIP has traditionally been studied for its role in blood sugar handling, newer research shows that GIP signaling also impacts fat tissue biology, insulin sensitivity, and appetite pathways. Merging GIP and GLP-1 receptor activity is thought to produce complementary benefits that optimize metabolic control while potentially easing digestive side effects relative to GLP-1 stimulation alone.[32]

The SURMOUNT clinical trial program looked at tirzepatide in patients with obesity and found dose-dependent weight drops that surpassed what most other anti-obesity drugs achieve. For adults without diabetes, higher doses of tirzepatide resulted in average weight reductions nearing 20% of their starting weight over about 72 weeks, accompanied by better waistlines, blood pressure, lipid levels, and metabolic indicators.[33]

Tirzepatide's striking effectiveness brings up important questions about how to choose treatments on an individualized basis. Patients struggling with obesity alongside heavy insulin resistance, prediabetes, or type 2 diabetes may see the greatest gains from therapies with robust metabolic action. On the other hand, individuals whose primary focus is appetite control, cardiovascular risk reduction, or keeping weight stable might need a different approach. Moving forward, clinical decision rules will likely focus on a patient's metabolic profile and specific goals instead of relying strictly on BMI numbers.

Other Approved Anti-obesity Medications

Even though incretin treatments currently lead the obesity care field, other medications remain clinically useful when taking individual patient traits into account. Orlistat, a gut lipase inhibitor, blocks dietary fat breakdown by stopping pancreatic and gastric enzymes. While it yields milder weight loss than newer options, it is still valued for its established safety record, absence of whole-body absorption, and possible heart health perks through better lipid profiles. However, digestive side effects like oily stools and sudden bowel urgency frequently hinder steady use.[34]

Naltrexone and bupropion combine in a brain-acting therapy that targets hypothalamic hunger regulation and reward pathways tied to eating. Bupropion activates proopiomelanocortin neurons, whereas naltrexone blocks opioid feedback controls to boost overall appetite reduction. This blend can prove particularly helpful for individuals who struggle with intense food cravings or reward-based eating patterns. Even so, doctors must exercise caution when prescribing it to patients with poorly controlled high blood pressure, seizure disorders, or certain mental health conditions.[35]

Phentermine and topiramate extended release combines a stimulant-like drug with an antiseizure medication that affects hunger control and fullness pathways. It yields clinically significant weight loss and can be considered for patients who need substantial reductions. Yet potential side effects, such as cognitive issues, mood shifts, and birth defect risks, require careful patient screening and ongoing monitoring.36 While these drugs typically produce less weight reduction than newer incretin therapies, they remain valuable elements of personalized obesity care. Choosing the right medication should rely not just on effectiveness, but on weighing expected benefits, safety, coexisting health conditions, cost, availability, and patient preference.

Integrating Pharmacotherapy With Patient Characteristics

Having more anti-obesity medications makes personalized care possible, but it also complicates clinical choices. Personalized drug treatment requires moving past the old habit of picking medications strictly by body mass index and instead looking at the broader clinical picture.

People dealing mainly with appetite control problems, constant hunger, or poor fullness signals often do better with drugs that hit central hunger circuits or incretin pathways. Patients with insulin resistance, prediabetes, or type 2 diabetes lean toward medications offering strong blood sugar control and metabolic support. On the other hand, individuals who cannot tolerate digestive side effects, have specific health restrictions, or lack access to injectable options need different routes.

Choosing drugs based on coexisting conditions matters because obesity seldom happens alone. Heart disease, diabetes, sleep apnea, metabolic dysfunction-associated steatotic liver disease, and kidney disease all steer medication choices and treatment targets. Recent proof showing heart and metabolic perks from specific incretin drugs has shifted obesity care away from simple weight loss and toward full disease management.[37]

Still, several hurdles stand in the way before tailored obesity pharmacotherapy becomes standard medical practice. Dependable biomarkers that forecast drug response remain scarce, genetic tests are not yet standard in obesity care, and high costs and healthcare gaps restrict access to top-tier medications. Upcoming treatment guidelines will need to combine clinical traits with molecular and digital markers to guide faster and more accurate drug selection.

Table 1. Currently Approved Pharmacological Therapies for Chronic Weight Management and Their Role in Personalized Treatment

Drug/Class	Mechanism	Weight Loss (%)	Suitable For
Semaglutide	GLP-1 receptor agonist	12–15	Obesity with/without type 2 diabetes; high weight-loss requirement
Liraglutide	GLP-1 receptor agonist	5–8	Patients requiring moderate weight loss
Tirzepatide	Dual GIP/GLP-1 receptor agonist	15–22	Severe obesity, insulin resistance, type 2 diabetes
Orlistat	Lipase inhibitor	3–5	Patients preferring oral therapy
Naltrexone/Bupropion	Appetite and reward pathway modulation	5–9	Emotional eating and food cravings
Phentermine/Topiramate ER	Appetite suppression	8–10	Patients requiring greater weight reduction

 

Patient Phenotyping and Precision Therapeutic Selection in Obesity

The growing complexity of obesity biology shows the shortcomings of old treatment strategies that rely mostly on body mass index (BMI). While BMI is still helpful for tracking excess fat across large populations and deciding treatment eligibility, it fails to show differences in fat spread, metabolic health, hunger control, or underlying disease drivers. Two people with the exact same BMI can face very different risks for diabetes, heart disease, liver problems, eating habits, and drug responses. Because of this, tailored obesity care requires moving past BMI-based categories toward multidimensional patient phenotyping.38

Phenotyping means systematically sorting individuals by their biological, metabolic, behavioral, and clinical traits that can shape how they respond to treatment. In obesity care, phenotypes offer a guide for picking medications according to the main factors driving weight gain and related health issues. Even though phenotype-led treatment is still developing, experts have proposed several clinically useful categories, including faulty fullness signals, reward-driven eating, slow resting metabolism, metabolic problems, and obesity triggered by secondary causes.39

 

 

Table 2. Phenotype-Based Approach for Personalized Obesity Pharmacotherapy

Obesity Phenotype	Key Characteristics	Therapeutic Considerations
Appetite-dominant phenotype	Persistent hunger, impaired satiety, frequent eating episodes	Prefer therapies targeting appetite regulation, including GLP-1-based treatments
Reward-driven eating phenotype	Food cravings, emotional eating, compulsive eating behavior	Consider therapies affecting central reward pathways combined with behavioral interventions
Metabolic dysfunction phenotype	Insulin resistance, prediabetes, type 2 diabetes, dyslipidemia, visceral adiposity	Select therapies with strong metabolic benefits, particularly incretin-based agents
Cardiometabolic risk phenotype	Cardiovascular disease, hypertension, high inflammatory burden	Prioritize agents with demonstrated cardiovascular benefit
Low energy expenditure phenotype	Reduced resting metabolic rate, weight-loss resistance	Requires intensive lifestyle support and consideration of therapies influencing energy balance
Severe obesity phenotype	Markedly elevated BMI, obesity complications, inadequate response to lifestyle therapy	Consider high-efficacy pharmacotherapy, combination approaches, or bariatric evaluation

 

Appetite and Satiety-Related Phenotypes

Disrupted appetite control stands as one of the most clinically significant drivers of obesity. People struggling with heightened hunger, diminished fullness, frequent food cravings, or trouble managing how much they eat often show deeper involvement in central hunger pathways and gut-brain signaling issues. Such individuals tend to see the greatest gains from treatments that boost satiety signals and curb appetite, including GLP-1 receptor agonists and dual incretin receptor agonists.

The success of incretin drugs stems partly from their capacity to fix flawed fullness responses by working through both peripheral and central pathways. Triggering GLP-1 receptors affects hypothalamic hunger centers and reward neural circuits, cutting calorie intake further than delayed stomach emptying alone can achieve.40 Yet differences in how people respond to appetite-focused treatments suggest that baseline eating habits and neurobehavioral traits shape overall results.

Eating is not governed entirely by physical hunger. Reward-seeking eating, emotional eating, stress-induced overeating, and food addiction behaviors engage dopamine and mesolimbic pathways that may not react the same way to standard appetite-suppressing drugs. Individuals whose eating patterns are mainly driven by pleasure or reward often need extra behavioral support or drug treatments that specifically target reward pathways, such as centrally acting medications.[41]

Metabolic Phenotyping and Insulin Resistance

Metabolic dysfunction serves as another critical factor in determining obesity-related risks and guiding treatment choices. People dealing with insulin resistance, hyperinsulinemia, dyslipidemia, and impaired glucose tolerance form a distinct subgroup where obesity heavily links with metabolic complications. These patients often gain special benefits from treatments that enhance insulin sensitivity and glucose handling alongside body weight reduction.

The difference between metabolically healthy obesity and metabolically unhealthy obesity highlights why metabolic phenotyping matters. Individuals sharing identical BMI numbers can vary widely in visceral fat, inflammation levels, liver fat storage, and cardiometabolic risk. Visceral fat accumulation, rather than total body weight by itself, shows a much stronger link to insulin resistance and the progression of metabolic disease.[42]

During clinical care, metabolic phenotyping can pull in measures like fasting blood sugar, glycated hemoglobin, lipid panels, blood pressure, liver enzymes, insulin resistance markers, and checks for related health complications. Even though advanced biomarkers like metabolomic panels and inflammatory markers look promising, their everyday use in clinics stays restricted because of high costs, limited availability, and a lack of uniform guidelines for reading results.

Body Fat Distribution and Adipose Tissue Phenotypes

Fat distribution and biological activity shape obesity-related health complications. Visceral fat is metabolically active and links to higher inflammation, insulin resistance, and heart disease risk, while subcutaneous fat usually carries less metabolic impact. As a result, people with identical BMIs but differing fat patterns can require entirely different treatment priorities.

Using imaging methods like CT scans, MRI, or DXA to check visceral fat provides detailed body composition insights, though these scans are not practical for every patient. More straightforward clinical measures, such as waist circumference and waist-to-height ratio, serve as helpful proxy markers for spotting individuals facing higher metabolic risk.[43]

Upcoming personalized treatment models might combine body composition checks with metabolic biomarkers to spot patients who need aggressive intervention despite having only moderate BMIs. This strategy holds special value for groups where metabolic health issues arise at lower BMI cutoffs.

Obesity Phenotypes Associated With Low Energy Expenditure

Lower resting metabolism and hindered adaptive thermogenesis act as extra drivers of weight gain and resistance to weight loss. Following weight reduction, certain individuals face drops in energy burn that outpace expected calculations, which encourages weight regain. This occurrence helps clarify why some patients experience limited long-term success despite faithfully following lifestyle changes and drug therapies. Being able to spot people who undergo marked metabolic slowing could help doctors determine how intense and long treatment should be. Even though checking resting energy expenditure directly via indirect calorimetry exists, its everyday clinic use stays restricted. Upcoming clinical tools that combine metabolic rate testing, wearable devices, and continuous physiological tracking may enhance how we identify these metabolic profiles.

Genetic and Pharmacogenomic-Based Treatment Selection

Bringing genetic data into obesity drug treatment forms a key pillar of precision medicine. Gene variants tied to appetite control, melanocortin signaling, dopamine pathways, and drug metabolism can shape both how susceptible someone is to obesity and how they react to therapy. Rare genetic conditions involving the leptin-melanocortin pathway already illustrate the clinical worth of mechanism-guided treatment choices. For instance, people with verified gene flaws affecting melanocortin-4 receptor signaling can react differently to focused treatments than individuals with typical polygenic obesity.44 Yet turning common gene variants into everyday prescribing choices remains difficult. Even though variations in genes like FTO and MC4R link to obesity risk, their skill at forecasting responses to particular anti-obesity drugs is still not proven enough for broad clinical application. Large-scale pharmacogenomic studies are needed to set up reliable genetic predictors of effectiveness, safety, and treatment longevity.

Comorbidity-Based Personalization

Obesity treatment should reach further than simple weight loss to encompass better control of weight-related health complications. As a result, choosing medications based on existing coexisting conditions stands out as one of the most clinically useful ways to personalize care today. Patients dealing with diagnosed heart disease can gain from drugs proven to lower cardiovascular risk, while those living with type 2 diabetes often need options that deliver both weight reduction and better blood sugar control. In the same way, individuals struggling with obesity-linked sleep apnea, metabolic dysfunction-associated steatotic liver disease, or elevated heart disease risk may need more aggressive strategies focused on wider metabolic health. The arrival of treatments offering disease-modifying benefits has moved the primary treatment goal from hitting a specific weight number toward enhancing overall health and wellbeing. This expanded viewpoint matches the view of obesity as a chronic condition demanding tailored, long-term care rather than a temporary push for weight reduction.[45]

Toward a Multidimensional Obesity Phenotyping Model

Moving forward, tailored drug treatment for obesity will likely depend on combining multiple clinical domains rather than relying on a single biomarker or classification system. A comprehensive phenotyping strategy might bring together:

• Anthropometric measures (BMI, waist circumference, body composition)
• Metabolic characteristics (glycemic status, insulin resistance, lipid profile)
• Behavioral factors (appetite regulation, eating patterns, psychological factors)
• Genetic and molecular information
• Comorbid disease profile
• Treatment preferences and socioeconomic factors

This kind of thorough evaluation can help doctors select the right treatment, forecast how well a patient will respond, and prevent patients from wasting time on ineffective medications. While achieving full precision medicine remains an ongoing goal, using patient phenotypes serves as a practical bridge toward genuinely personalized obesity care.

EMERGING THERAPEUTIC ALGORITHMS AND NOVEL PHARMACOLOGICAL APPROACHES

The fast growth of anti-obesity medications has brought both new opportunities and new hurdles to clinical choices. Although having access to highly effective drugs improves results, the sheer volume of choices calls for a structured method to pick the right medication. Medical practice is slowly moving away from the old trial-and-error method toward algorithm-guided treatment choices that factor in obesity severity, metabolic traits, coexisting conditions, treatment goals, safety concerns, and patient preferences.

A customized treatment algorithm should treat obesity as a chronic condition needing long-term oversight rather than a quick fix for weight loss. Because of this, medical choices must weigh not only how much weight someone is expected to drop, but also gains in metabolic health, heart disease risk, quality of life, physical functioning, and the ability to stick with treatment over the long haul.

Investigational Therapy	Target Pathway	Current Development Status	Potential Advantages
Retatrutide	GLP-1/GIP/glucagon triple receptor agonist	Late-stage clinical development	Combines appetite suppression with increased energy expenditure and metabolic effects
CagriSema	GLP-1 receptor agonist + amylin analogue	Advanced clinical evaluation	Dual hormonal approach targeting satiety and appetite control
MariTide (AMG-133)	Long-acting GLP-1 receptor agonist activity	Clinical development	Less frequent dosing may improve adherence
Next-generation amylin analogues	Amylin receptor pathway	Early-to-late clinical development	Potential complementary effects with incretin therapies
Multi-agonist peptide therapies	Multiple gut hormone receptors	Experimental/clinical development	Potential for greater efficacy through simultaneous pathway modulation

 

Evolution From Conventional Treatment Pathways to Personalized Algorithms

Older obesity treatment rules relied mostly on body mass index thresholds to decide who qualifies for drug therapy. Even though BMI is still handy for spotting people who could use treatment, it tells us very little about the biological drivers of the disease or how a patient will react to medication.51 Modern methods lean much more toward thorough evaluations, factoring in the specific obesity phenotype, related metabolic issues, past weight loss efforts, eating habits, medication history, and personal goals.[52]

A functional personalized care path starts by confirming the obesity diagnosis, checking for related health complications, ruling out underlying causes of weight gain, and flagging any elements that shape drug choice. Such factors involve heart disease risk, diabetes status, kidney and liver health, mental health conditions, reproductive factors, cost, and availability.[53]

Once this initial check is complete, medication should be picked based on the main treatment goal. For instance, patients dealing with obesity and diagnosed heart disease might lean toward drugs proven to lower cardiovascular risk, while those struggling with heavy insulin resistance or type 2 diabetes will likely need agents that deliver major metabolic improvements. Meanwhile, individuals whose main issue is faulty hunger control often do best with therapies that target central fullness pathways.

Combination Pharmacotherapy and Multimodal Approaches

Because body weight is governed by intricate biological networks, single-target treatments often fall short of producing long-term weight loss.54 Since obesity stems from overlapping physiological drivers, including appetite control, energy balance, insulin response, fat tissue function, and neural reward circuits, combining agents with complementary mechanisms is becoming a necessary clinical strategy.

Dual and multi-drug regimens have already proven effective in practice. For instance, pairing naltrexone with bupropion successfully influences distinct central nervous system pathways to curb cravings and alter food reward responses.[54]In parallel, emerging treatments pair incretin pathways with other gut or metabolic hormones to boost therapeutic efficacy while keeping side effects manageable.[55]

Multi-drug approaches are particularly valuable for patients with severe obesity, those who fail to respond to single agents, or individuals who need substantial and lasting weight reduction. Even so, future clinical research must establish the best treatment sequences, dosing regimens, long-term safety profiles, and cost-effectiveness of these combination therapies.

Next-generation Incretin-based Therapies

Retatrutide: Triple Hormonal Receptor Agonism

Retatrutide functions as an investigational triple agonist designed to stimulate the GLP-1, GIP, and glucagon receptors.56 While standard incretin treatments mainly increase fullness and regulate glucose levels, activating the glucagon receptor also stimulates energy expenditure, improves lipid processing, and decreases fat accumulation in the liver.

Clinical trials indicate that retatrutide produces significant weight reduction, with higher doses achieving average weight losses that approach or exceed those seen with existing approved medications. The primary advantage of activating all three receptors simultaneously is its dual mechanism of curbing calorie intake while driving up energy burn, tackling two core drivers of obesity.[56]

Despite these promising results, several questions remain open regarding long-term safety, ideal dosing schedules, how well weight loss is maintained after stopping the drug, and which patient groups stand to gain the most. As with any potent therapy, tailoring treatment to the individual will be crucial to balance high efficacy against potential side effects.

CagriSema: Combining Amylin and GLP-1 Pathways

CagriSema pairs semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analogue, utilizing amylin as a pancreatic hormone released alongside insulin to help control appetite, slow stomach emptying, and promote fullness. The combination works because their physiological effects complement one another: while GLP-1 receptor activation strongly suppresses hunger and improves glucose metabolism, amylin signaling enhances satiety through separate central pathways. Although clinical trials show that CagriSema delivers promising weight-loss results that highlight the advantages of multi-hormonal over single-pathway strategies, comparative effectiveness studies remain necessary to establish whether these combinations offer true clinical superiority over current high-efficacy treatments.[57]

MariTide and Long-acting Therapeutic Strategies

MariTide, formally known as maridebart cafraglutide, is an investigational agent that engages the GLP-1 receptor utilizing antibody-peptide conjugation technology.[58] Its prolonged pharmacological profile has attracted significant clinical interest because extended dosing intervals could greatly enhance patient convenience and adherence.[58]

Because sustaining treatment adherence poses a persistent challenge in chronic disease care, long-acting drug designs offer a promising avenue to boost persistence in obesity regimens . Even so, comprehensive long-term safety data and head-to-head comparisons with established treatments are necessary prior to widespread clinical adoption.

Beyond Incretins: Emerging Biological Targets

Although incretin-based therapies currently dominate obesity pharmacotherapy, future treatment strategies are likely to involve multiple biological targets.

Amylin Pathway Modulation

Amylin mimetics hold significant promise for weight management owing to their capacity to boost fullness and govern calorie intake. Beyond serving in combination treatments, newer amylin-based medications could offer alternative therapeutic pathways for patients who respond poorly to standard incretin regimens.[59]

Leptin–Melanocortin Pathway

The leptin-melanocortin axis acts as a vital controller of hunger and energy expenditure. Although administering synthetic leptin yields minimal success in common forms of obesity due to underlying leptin resistance, precision therapies designed for rare genetic conditions that impair melanocortin signaling underscore the necessity of mechanism-driven treatment choices.[60]

Glucagon and Energy Expenditure Pathways

Activating the glucagon receptor offers another encouraging therapeutic strategy because it can increase energy expenditure, promote lipid burning, and improve liver metabolism. At the same time, careful evaluation is required to weigh these metabolic advantages against potential drawbacks, such as elevated heart rates or rising blood glucose levels.[61]

Artificial Intelligence and Data-driven Therapeutic Algorithms

Artificial intelligence and machine learning are increasingly being studied to enhance personalized care for obesity. In contrast to standard clinical guidelines that rely on a handful of variables, advanced computational models can process extensive, multi-layered data sources, such as electronic health records, genetic markers, laboratory results, medical imaging, wearable device metrics, and behavioral profiles.[62,63]

Potential applications include forecasting individual weight-loss outcomes, spotting patients at risk of stopping treatment early, refining drug choices, and recognizing early treatment failure. Ultimately, machine learning algorithms may support physicians by generating tailored therapeutic recommendations based on complex patterns that are difficult to spot through routine clinical evaluation.[64]

Nonetheless, adopting AI-driven strategies requires rigorous validation across diverse patient populations, model transparency, strict safeguards for personal privacy, and seamless integration into daily clinical workflows. For now, artificial intelligence should serve as a supportive decision-aid rather than a substitute for professional clinical judgment.

Future Framework for Personalized Obesity Treatment Algorithms

A future precision obesity algorithm may incorporate sequential decision-making:

Step 1: Comprehensive phenotyping

• BMI and waist circumference
• Body composition
• Metabolic profile
• Eating behavior assessment
• Comorbidity evaluation
• Genetic and biomarker assessment when clinically appropriate.65-67

Step 2: Define therapeutic priorities

• Maximum weight reduction
• Cardiometabolic risk reduction
• Glycemic improvement
• Reduction of obesity complications
• Improvement in quality of life.68

Step 3: Select mechanism-based therapy

• Appetite-dominant phenotype → appetite-regulating therapies
• Metabolic dysfunction phenotype → therapies with strong metabolic effects
• Cardiovascular disease phenotype → agents with demonstrated cardiovascular benefit
• Severe obesity phenotype → high-efficacy or combination approaches.69-70

Step 4: Continuous reassessment

Assessing treatment success involves monitoring weight changes, metabolic health gains, side effects, medication adherence, and patient-reported outcomes. When a patient fails to show meaningful improvement, clinicians should review treatment adherence, re-evaluate their phenotypic classification, and explore alternative biological mechanisms instead of indefinitely continuing a regimen that is not working.[71]

Challenges in Implementing Personalized Therapeutic Algorithms

Despite significant headway, several obstacles continue to slow the broader implementation of precision obesity medicine. Reliable biomarkers capable of forecasting individual drug responses remain scarce, pharmacogenomic tools are still mostly exploratory, and many newer treatments encounter major hurdles related to high costs, limited availability, and healthcare disparities.72-74

Furthermore, obesity care takes place within intricate social and environmental settings. Tailored pharmacotherapy should therefore extend beyond simply choosing a medication, encompassing the integration of biological data with behavioral, psychological, and socioeconomic factors.75

Looking ahead, obesity medicine is expected to adopt adaptive treatment strategies where drug regimens are continually refined based on shifting patient profiles and ongoing therapeutic responses. Such evolution has the potential to shift clinical practice away from trial-and-error prescribing toward evidence-based precision care.[76]

Current Challenges and Future Directions in Personalized Obesity Pharmacotherapy

Although pharmacotherapy for obesity has progressed remarkably, personalized treatment strategies are still in their infancy. The arrival of highly potent incretin-based medications and newer agents has raised expectations for weight loss, yet translating these gains into everyday clinical practice requires surmounting biological, clinical, technological, and systemic hurdles. Ultimately, the success of precision obesity medicine relies not only on creating more potent drugs, but also on pinpointing which patients will benefit most, establishing ideal treatment sequences, and securing fair access to these therapies for everyone.[77-79]

Limited Availability of Predictive Biomarkers

One primary hurdle in personalized obesity pharmacotherapy is the lack of validated biomarkers capable of reliably forecasting how a patient will respond to treatment.[80] Although various biological metrics such as gene variants, hormone levels, inflammatory markers, and metabolic profiles are linked to obesity vulnerability, their utility in guiding drug selection is not yet fully established.[81]

Unlike fields such as oncology where molecular markers routinely dictate treatment choices, obesity care still depends heavily on broad clinical markers like body mass index, coexisting conditions, and prior treatment response. For example, even though factors such as GLP-1 receptor presence, gut hormone levels, and insulin resistance theoretically affect how well a patient reacts to incretin treatments, these metrics are not yet integrated into standard clinical decision-making.

Future research should focus on identifying clinically applicable biomarkers that can predict:

• magnitude of weight reduction,
• likelihood of treatment discontinuation,
• risk of adverse effects,
• durability of response,
• and optimal therapeutic combinations.

Combining metabolomics, proteomics, transcriptomics, and microbiome profiling could yield a much deeper understanding of how individual patients respond to treatment. Even so, these sophisticated approaches must undergo extensive, large-scale validation before they can be integrated into standard clinical care for obesity.[82]

 

Table 4. Potential Biomarkers and Precision Medicine Tools in Obesity Pharmacotherapy

Precision Medicine Component	Potential Clinical Application	Current Status
Genetic variants (MC4R, FTO, PCSK1, others)	Prediction of obesity susceptibility and possible treatment response	Research stage; insufficient evidence for routine prescribing
Metabolic markers (glucose, insulin resistance indices, lipid profile)	Identification of metabolically high-risk patients and treatment prioritization	Clinically available
Body composition assessment	Differentiation of visceral adiposity and metabolic risk	Increasing clinical application
Gut microbiome profiling	Prediction of metabolic phenotype and treatment response	Experimental
Multi-omics approaches (genomics, proteomics, metabolomics)	Comprehensive biological characterization	Research stage
Digital biomarkers from wearable devices	Monitoring adherence, activity, and treatment response	Emerging clinical application
Artificial intelligence models	Prediction of treatment response and personalized decision support	Developing technology

 

Challenges in Pharmacogenomics and Precision Medicine

Pharmacogenomics offers an encouraging framework for spotting genetic factors that govern how patients respond to obesity medications. Genetic variations can shape processes like appetite control, drug breakdown, receptor function, and side-effect vulnerability. Nevertheless, unlike in other medical fields where genetic testing is firmly established, pharmacogenomics in obesity remains purely exploratory.[83-85]

The fact that typical obesity is polygenic introduces major obstacles. Most gene variants linked to obesity exert only minor individual influences, making their practical value for selecting specific drugs uncertain. Furthermore, genetic predisposition constantly interacts with external factors such as environment, diet, exercise, psychological state, and socioeconomic status, which complicates any attempt to forecast therapeutic outcomes.[86,87]

Upcoming studies will require large, diverse populations to establish whether genetic data can meaningfully enhance treatment choices beyond current clinical tools. While validated polygenic scores and genetic algorithms could eventually advance customized treatment, routine DNA-guided prescribing is unlikely until more robust clinical proof is established.[88,89]

Long-term Treatment Sustainability and Weight Regain

Sustaining weight loss over time remains a major hurdle in obesity treatment. Because obesity is a chronic condition driven by biological forces that actively resist weight reduction, stopping drug therapy frequently leads to partial or total weight regain as hunger cues return, energy burning slows, and compensatory metabolic pathways reactivate.[90,91] Although clinical trials show that incretin therapies produce substantial weight loss while active, follow-up studies confirm that stopping treatment typically triggers weight recovery.90,92 These outcomes underscore the reality that, much like treatments for hypertension or type 2 diabetes, long-term medication use is often necessary to achieve lasting disease control.[91,93]

This creates important clinical questions regarding:

• the optimal duration of therapy,
• strategies for dose reduction or maintenance therapy,
• identification of patients requiring lifelong treatment,
• and approaches to preserve weight loss after medication discontinuation.

Future personalized algorithms should therefore incorporate not only medication initiation but also long-term maintenance strategies.[90,92]

Safety Considerations and Individual Risk Assessment

Although modern anti-obesity drugs feature safer profiles than older agents, personalized risk evaluation remains indispensable. The expanding use of highly potent treatments necessitates careful observation for potential side effects, contraindications, and long-range implications.[94,95]

Gastrointestinal symptoms continue to be the primary constraint for incretin-based regimens and can negatively affect patient adherence.[96] Furthermore, rapid weight reduction frequently leads to altered body composition, including losses in lean muscle mass, underscoring the necessity of combining drug therapy with resistance training and sufficient dietary protein.[97,98]

Additional considerations include:

• reproductive safety,
• interactions with concomitant medications,
• nutritional status,
• psychological effects,
• effects on eating behavior,
• and suitability in elderly individuals or those with complex comorbidities.94,95,99,100

Personalized treatment should therefore consider not only expected efficacy but also the individual's risk profile and capacity to sustain therapy.[94,95]

 

 

Table 5. Proposed Clinical Algorithm for Personalized Obesity Pharmacotherapy

Step	Clinical Assessment	Therapeutic Decision
1. Confirm diagnosis and severity	BMI, waist circumference, body composition, obesity complications	Determine need for pharmacotherapy
2. Identify obesity phenotype	Appetite pattern, metabolic profile, eating behavior, comorbidities	Match therapy with dominant disease mechanism
3. Evaluate treatment priorities	Weight reduction, glycemic control, cardiovascular risk reduction, quality of life	Define individualized therapeutic goals
4. Select pharmacotherapy	Consider efficacy, safety, contraindications, affordability, patient preference	Choose appropriate medication class
5. Monitor response	Weight trajectory, metabolic improvement, adverse effects, adherence	Continue, adjust, or change therapy
6. Long-term management	Maintenance strategy and prevention of weight regain	Chronic disease management approach

 

Cost, Accessibility, and Healthcare Inequality

The growing potency of anti-obesity drugs has brought major hurdles regarding cost and fair access. Because numerous highly effective treatments remain costly and insurance policies differ widely, advanced pharmacotherapy often stays out of reach for individuals with fewer financial resources, which risks exacerbating existing health disparities.[101,102]

Furthermore, while obesity disproportionately impacts socioeconomically disadvantaged communities, these same groups frequently encounter barriers to specialized care, organized weight-management programs, and novel medications. Consequently, any true precision medicine framework must actively integrate measures to enhance both affordability and accessibility.[103,104]

Future priorities should include:

• development of cost-effective treatment pathways,
• broader insurance coverage,
• availability of affordable generic or alternative therapies,
• integration of obesity care into primary healthcare systems,
• and consideration of population-specific treatment needs.[101,103,105]

 

Integration of Digital Health and Remote Monitoring

Digital health innovations offer fresh avenues for refining tailored obesity care. Wearables, mobile apps, continuous glucose monitors, and remote monitoring tools capture real-time data regarding physical activity, dietary patterns, sleep cycles, metabolic function, and treatment adherence.[106,107]

Such tools can elevate personalized care by letting clinicians dynamically track how a patient responds and intervene promptly when weight loss stalls or adherence drops.[108,109] Combining these digital indicators with electronic health records and artificial intelligence platforms could enable adaptive treatment models that continually refine therapeutic advice.[110,111]

Nevertheless, hurdles persist surrounding data precision, user engagement, privacy, cybersecurity, and smooth incorporation into standard clinical workflows. Ultimately, digital interventions should serve to complement rather than supersede clinician-directed care.[114]

Future Role of Artificial Intelligence and Predictive Analytics

Artificial intelligence stands poised to become a central pillar of tomorrow's precision-based obesity care. By leveraging machine learning models, healthcare systems can parse intricate datasets spanning clinical records, genetic profiles, behavioral tendencies, and environmental factors to uncover specific patterns linked to treatment response.[115,116]

Potential applications include:

• predicting individual response to specific medications,
• identifying optimal drug combinations,
• forecasting weight regain risk,
• optimizing treatment adherence strategies,
• and supporting clinical decision-making.

Before artificial intelligence can be reliably adopted in clinical obesity care, several hurdles must be cleared, including thorough algorithm validation, model transparency, bias mitigation, data standardization, and proof that patient outcomes surpass traditional methods.

The most probable outlook involves AI-powered decision support, where smart algorithms serve to augment rather than supplant physician expertise.

Transition Toward Dynamic Precision Obesity Medicine

Future obesity care is poised to shift away from static classification frameworks toward dynamic disease management. Rather than locking patients into fixed treatment categories, emerging strategies will continuously synthesize evolving clinical and biological data to refine therapy dynamically as the condition progresses.[117,118]

A dynamic precision model may involve:

1. Initial comprehensive phenotyping

• metabolic status,
• obesity subtype,
• comorbidities,
• behavioral characteristics.

2. Mechanism-based medication selection

• choosing therapies aligned with dominant disease pathways.

3. Response monitoring

• evaluating weight trajectory,
• metabolic improvements,
• adverse effects,
• adherence.

4. Therapeutic adaptation

• adjusting dose,
• switching agents,
• adding combination therapy,
• implementing maintenance strategies.

Such an approach acknowledges that obesity biology changes over time and that treatment should evolve accordingly.[117,119]

Future Research Priorities

Several areas require further investigation before personalized obesity pharmacotherapy becomes standard clinical practice:

• Identification and validation of predictive biomarkers.
• Large-scale pharmacogenomic studies linking genetic profiles with medication response.
• Comparative effectiveness studies between emerging therapies.
• Long-term safety studies extending beyond clinical trial periods.
• Development of clinically practical phenotyping tools.
• Integration of artificial intelligence into validated clinical workflows.
• Evaluation of cost-effectiveness and healthcare accessibility.

Addressing these gaps will be essential for translating precision medicine concepts into real-world obesity care.

CONCLUSION

Personalized pharmacotherapy marks a crucial turning point in obesity management, moving away from broad, one-size-fits-all weight-loss methods and toward targeted, mechanism-driven strategies. While breakthroughs in incretin-based medications and multi-target agents have broadened therapeutic options, varied patient responses underscore the ongoing need for precision.

Looking ahead, obesity care will likely rely on combining clinical phenotyping, molecular markers, pharmacogenomics, digital tools, and artificial intelligence into unified treatment frameworks. Although several elements of precision medicine are still evolving, ongoing progress in biotechnology and clinical science offers a clear pathway to make obesity management more effective, individualized, and sustainable as a chronic disease model.

REFERENCES

1. Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221-262. doi:10.1016/S2213-8587(24)00316-4.

2. World Health Organization. Obesity and overweight. Geneva: WHO; 2024.

3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027-1050. doi:10.1016/S0140-6736(23)02750-2.

4. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation; 2025.

5. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation. 2014;129(Suppl 2):S102–S138.

6. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002.

7. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216.

8. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity (STEP 8). JAMA. 2022;327:138–150.

9. Acosta A, Streett S, Kroh MD, Cheskin LJ, Saunders KH, Kurian M, et al. White Paper AGA: Power of Obesity Phenotyping in Precision Medicine. Clin Gastroenterol Hepatol. 2021;19:2141–2153.

10. Acosta A, Camilleri M. Precision medicine in obesity. Gastroenterology. 2023;164:1223–1237.

11. Espinosa MA, Rivera Gutierrez RJ, Villamarin J, Acosta A. Precision medicine for obesity treatment. J Endocr Soc. 2025;9(9):bvaf102. doi:10.1210/jendso/bvaf102.

12.  Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. Triple-hormone receptor agonism with retatrutide in adults with obesity. N Engl J Med. 2023;389:514–526.

13. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25:44–56.

14. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–298.

15. Morton GJ, Meek TH, Schwartz MW. Neurobiology of food intake in health and disease. Nat Rev Neurosci. 2014;15(6):367–378.

16. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404(6778):661–671.

17. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–223.

18. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.

19. Kahn CR, Wang G, Lee KY. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest. 2019;129(10):3990–4000.

20. Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197–206.

21. Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120–133.

22. Ling C, Rönn T. Epigenetics in human obesity and type 2 diabetes. Cell Metab. 2019;29(5):1028–1044.

23. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19:55–71.

24. Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018;67(9):1716–1725.

25. Acosta A, Camilleri M, Abu Dayyeh BK, Calderon G, Gonzalez D, McRae A, et al. Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic. Obesity (Silver Spring). 2021;29(4):662-671. doi:10.1002/oby.23120.

26. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597–1604.

27. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of Clinical Endocrinology and American College of Endocrinology clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 Suppl 3:1-203.

28. Anazco D, Acosta A. Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy. Int J Obes (Lond). 2025;49(3):452-463. doi:10.1038/s41366-024-01599-z.

29. Holst JJ. The physiology of glucagon-like peptide-1. Physiol Rev. 2007;87:1409–1439.

30. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373:11–22.

31. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002.

32. Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023;19:201-216. doi:10.1038/s41574-022-00783-3.

33. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216.

34. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27:155–161.

35. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults. Lancet. 2010;376:595–605.

36. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release phentermine plus topiramate on weight loss. Lancet. 2011;377:1341–1352.

37. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563.

38. Blüher M. Metabolically healthy obesity. Endocr Rev. 2020;41(3):bnaa004. doi:10.1210/endrev/bnaa004.

39. Koufakis T, Busetto L. From one-size-fits-all to phenotype-based pharmacotherapy: How far are we in obesity management? Curr Opin Pharmacol. 2026;86:102589. doi:10.1016/j.coph.2025.102589.

40. Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. doi:10.1016/j.molmet.2019.09.010.

41. Volkow ND, Wang GJ, Tomasi D, Baler RD. Obesity and addiction: neurobiological overlaps. Obes Rev. 2013;14(1):2-18. doi:10.1111/j.1467-789X.2012.01031.x.

42. Stefan N, Häring HU, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1(2):152-162. doi:10.1016/S2213-8587(13)70062-7.  

43. Neeland IJ, Ross R, Després JP, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715-725. doi:10.1016/S2213-8587(19)30084-1.

44. Kühnen P, Wiegand S, Biebermann H, Hinney A, Tschöp MH, Grüters A, et al. The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options. Obes Rev. 2013;14(2):96-109. doi:10.1111/obr.12006.

45. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224.

46. Goodarzi MO. Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications. J Intern Med. 2018;284(5):525-538. doi:10.1111/joim.12896.

47. Tuccinardi D, Masi D, Watanabe M, Zanghi Buffi V, De Domenico F, Berti S, et al. Precision obesity medicine: a phenotype-guided framework for pharmacologic therapy across the lifespan. J Endocrinol Invest. 2025;48(12):2761-2798. doi:10.1007/s40618-025-02700-7.

48. Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, et al. The science of obesity management: an Endocrine Society scientific statement. Endocr Rev. 2018;39(2):79-132. doi:10.1210/er.2017-00253.

49. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254-266. doi:10.1056/NEJMra1514009.

50. Ryan DH, Kahan S. Guideline recommendations for obesity management. Med Clin North Am. 2018;102(1):49-63. doi:10.1016/j.mcna.2017.08.006.

51. Hocking S, Sumithran P. Individualised prescription of medications for treatment of obesity in adults. Rev Endocr Metab Disord. 2023;24(5):951-960. doi:10.1007/s11154-023-09808-2.

52. Acosta A, Streett S, Kroh MD, Cheskin LJ, Saunders KH, Kurian M, et al. White Paper AGA: Power of obesity phenotyping in precision medicine. Clin Gastroenterol Hepatol. 2021;19(11):2141-2153.

53. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201-223.

54. Steenackers N, Toumassian J, Deleus E, Mertens A, Lannoo M, Pazmino S, et al. Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals? Front Endocrinol (Lausanne). 2025;16:1569468. doi:10.3389/fendo.2025.1569468.

55. Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025;393(7):635-647. doi:10.1056/NEJMoa2502081.

56. Kaur M, Misra S. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol. 2024;80(5):669-676. doi:10.1007/s00228-024-03646-0.

57. Frias JP, Bastyr EJ, Vignati L, et al. The once-weekly amylin analogue cagrilintide, alone or combined with semaglutide, for obesity treatment: a phase 1b, randomised, controlled trial. Lancet. 2021;397(10286):1736-1748.

58. Jastreboff AM, Ryan DH, Bays HE, Ebeling PR, Mackowski MG, Philipose N, et al.; MariTide Phase 2 Obesity Trial Investigators. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. N Engl J Med. 2025;393(9):843-857. doi:10.1056/NEJMoa2504214.

59. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev. 2015;67(3):564-600. doi:10.1124/pr.115.010629.

60. Sun Y, Abed M, Sohouli MH. The effect of melanocortin-4 receptor agonist drugs on obesity and metabolic risk factors: a systematic review and meta-analysis. Diabetol Metab Syndr. 2026;18(1):40. doi:10.1186/s13098-025-02071-2.

61. Hope DC, Tan TMM. Glucagon and energy expenditure: revisiting amino acid metabolism and implications for weight loss therapy. Peptides. 2023;162:170962. doi:10.1016/j.peptides.2023.170962.

62. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25:44-56.

63. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019;25:24-29.

64. Beam AL, Kohane IS. Big data and machine learning in health care. JAMA. 2018;319:1317-1318.

65. Anazco D, Acosta A. Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy. Int J Obes (Lond). 2025;49(3):452-463. doi:10.1038/s41366-024-01599-z.

66. Acosta A, Streett S, Kroh MD, Cheskin LJ, Saunders KH, Kurian M, et al. White Paper AGA: Power of obesity phenotyping in precision medicine. Clin Gastroenterol Hepatol. 2021;19(11):2141-2153.

67. Blüher M. Metabolically healthy obesity. Endocr Rev. 2020;41(3):bnaa004.

68. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, Wadden TA, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138-150.

69. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.

70. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221-2232.

71. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for Pharmacological Management of Obesity. Endocr Pract. 2022;28(9):923-1049.

72. Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120-133.

73. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288-298.

74. Anazco D, Acosta A. Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy. Int J Obes (Lond). 2025;49(3):452-463. doi:10.1038/s41366-024-01599-z.

75. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.

76. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038.

77. Acosta A, Camilleri M. Precision medicine in obesity. Gastroenterology. 2023;164(6):1223-1237.

78. Cifuentes L, Anazco D, O'Connor T, Hurtado MD, Ghusn W, Campos A, et al. Genetic and physiological insights into satiation variability predict responses to obesity treatment. Cell Metab. 2025;37(8):1655-1666.e5. doi:10.1016/j.cmet.2025.05.008.

79. Jansen PR, Vos N, van Uhm J, Dekkers IA, van der Meer R, Mannens MMA, et al. The utility of obesity polygenic risk scores from research to clinical practice: a review. Obes Rev. 2024;25(11):e13810. doi:10.1111/obr.13810.

80. Cordero P, Li L, Oben JA. Obesity, epigenetics and precision medicine. Clin Epigenetics. 2022;14:121. doi:10.1186/s13148-022-01339-0.

81. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18:83.

82. Yeo GSH. Genetics of obesity: what have we learned? Nat Rev Endocrinol. 2021;17(7):423-436. doi:10.1038/s41574-021-00529-5.

83. Anazco D, Acosta A. Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy. Int J Obes (Lond). 2025;49(3):452-463. doi:10.1038/s41366-024-01599-z.

84. Vettori A, Pompucci G, Garagnani P, Franceschi C, Di Blasio AM. Genetic background, nutrition and obesity: a review. Eur Rev Med Pharmacol Sci. 2019;23(4):1751-1761. doi:10.26355/eurrev_201902_17137.

85. Kiseleva OI, Pyatnitskiy MA, Arzumanian VA, Kurbatov IY, Ilinsky VV, Ilgisonis EV, et al. Multiomics picture of obesity in young adults. Biology (Basel). 2024;13(4):272. doi:10.3390/biology13040272.

86. Wallis N, Raffan E. The genetic basis of obesity and related metabolic diseases in humans and companion animals. Genes (Basel). 2020;11(11):1378. doi:10.3390/genes11111378.

87. Oussaada SM, van Galen KA, Cooiman MI, Kleinendorst L, Hazebroek EJ, van Haelst MM, et al. The pathogenesis of obesity. Metabolism. 2019;92:26-36. doi:10.1016/j.metabol.2018.12.012.

88. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.

89. Huang L, Huhulea EN, Abraham E, Bienenstock R, Aifuwa E, Hirani R, et al. The role of artificial intelligence in obesity risk prediction and management: approaches, insights, and recommendations. Medicina (Kaunas). 2025;61(2):358. doi:10.3390/medicina61020358.

90. Wharton S, Rössner S, Birch DW, et al. Individualised prescription of medications for treatment of obesity in adults. Lancet Diabetes Endocrinol. 2023;11(8):569-579. doi:10.1016/S2213-8587(23)00114-4.

91. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945.

92. Ogunsakin AA, Olakunde TI, Fehintola MD, Malmberg I, Olakunde A, Dokun AO. Updates in pharmacotherapy of obesity. J Natl Med Assoc. 2024;116(5):576-587. doi:10.1016/j.jnma.2024.09.004.

93. Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ. 2025;197(27):E797-E809. doi:10.1503/cmaj.250502.

94. Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ. 2025;197(27):E797-E809. doi:10.1503/cmaj.250502.

95. Qaseem A, Cross JT Jr, Harrod CS, Owens DK, Balk EM, Crandall CJ; Clinical Guidelines Committee of the American College of Physicians. Pharmacologic treatments with lifestyle modifications in nonpregnant adults with overweight or obesity in outpatient settings: a living clinical guideline from the American College of Physicians (April 2026). Ann Intern Med. 2026 Jun 16. doi:10.7326/ANNALS-25-02714.

96. Wharton S, Davies M, Dicker D, Lingvay I, Misra A, Rubino DM, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. doi:10.1111/dom.14551.

97. Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother. 2024;25(5):611-619. doi:10.1080/14656566.2024.2343092.

98. Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2025;164:156113. doi:10.1016/j.metabol.2024.156113.

99. American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S145-S157.

100. Di Vincenzo O, Minnetti M, Baker JL, Barazzoni R, Boyland E, Busetto L, et al. European Association for the Study of Obesity position statement on the diagnosis and management of obesity in older adults. Obes Facts. 2025 Nov 27:1-16. doi:10.1159/000549751.

101. Herges JR, Neumiller JJ, McCoy RG. Navigating cost and access barriers for medications in the treatment of obesity: a guide for patients and primary care clinicians. Clin Diabetes. 2025;43(4):587-596. doi:10.2337/cd24-0115.

102. Waldrop SW, Johnson VR, Stanford FC. Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity. Nat Med. 2024;30(1):22-25. doi:10.1038/s41591-023-02669-x.

103. Burguera B, Griebeler ML, Garvey WT. Effective but inaccessible antiobesity medications: a call for sharing responsibility for improving access to evidence-based care. Cleve Clin J Med. 2024;91(11):671-676. doi:10.3949/ccjm.91a.24068.

104. Ross KM, Worwag KE, Swanson TN, Shetty A, Barrett KL. Health disparities in obesity treatment outcomes, access, and utilization. Curr Obes Rep. 2025;14(1):47. doi:10.1007/s13679-025-00639-7.

105. Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024;403(10434):e21-e31. doi:10.1016/S0140-6736(24)00351-9.

106. Protano C, De Giorgi A, Valeriani F, Mazzeo E, Zanni S, Cofone L, et al. Can digital technologies be useful for weight loss in individuals with overweight or obesity? A systematic review. Healthcare (Basel). 2024;12(6):670. doi:10.3390/healthcare12060670.

107. Cheah KJ, Abdul Manaf Z, Mat Ludin AF, Razalli NH. Potential role of hybrid weight management intervention: a scoping review. Digit Health. 2024;10:20552076241258366. doi:10.1177/20552076241258366.

108. Li SJ, Zhou Y, Ma HM, Wang AQ, Tang XY, Pei RY, et al. Effects of mobile applications on weight-related, behavior and metabolic outcomes for adults with overweight and obesity: a systematic review and meta-analysis. Stud Health Technol Inform. 2024;315:386-391. doi:10.3233/SHTI240175.

109. Herring SJ, Cruice JF, Bennett GG, Davey A, Foster GD. Using technology to promote healthy eating and physical activity in behavioral weight loss programs: a systematic review. J Med Internet Res. 2014;16(9):e217.

110. Azmi S, Kunnathodi F, Alotaibi HF, Alhazzani W, Mustafa M, Ahmad I, et al. Harnessing artificial intelligence in obesity research and management: a comprehensive review. Diagnostics (Basel). 2025;15(3):396. doi:10.3390/diagnostics15030396.

111. Ghosh J, Gudzune KA, Schwartz JL. Electronic health records tools for treating obesity among adult patients in primary care: a scoping review. Obes Pillars. 2025;13:100161. doi:10.1016/j.obpill.2025.100161.

112. Teke J, Msiska M, Adanini OA, Egbon E, Osborne A, Olawade DB. Artificial intelligence for obesity management: a review of applications, opportunities, and challenges. Obes Med. 2025;58:100657. doi:10.1016/j.obmed.2025.100657.

113. Iwaya LH, Ahmad A, Babar MA. Security and privacy for mHealth and uHealth systems: a systematic mapping study. Comput Secur. 2020;97:101861. doi:10.1016/j.cose.2020.101861.

114. World Health Organization. Ethics and governance of artificial intelligence for health: WHO guidance. Geneva: World Health Organization; 2021. 150 p. ISBN: 978-92-4-002920-0.

115. Kim DW, Park CY, Shin JH, Lee HJ. The role of artificial intelligence in obesity medicine. Endocrinol Metab Clin North Am. 2025;54(1):207-215. doi:10.1016/j.ecl.2024.10.008.

116. Shahabi F, Battalio SL, Pfammatter AF, Hedeker D, Spring B, Alshurafa N. A machine-learned model for predicting weight loss success using weight change features early in treatment. NPJ Digit Med. 2024;7:344. doi:10.1038/s41746-024-01299-y.

117. Tuccinardi D, Masi D, Watanabe M, Zanghi Buffi V, De Domenico F, Berti S, et al. Precision obesity medicine: a phenotype-guided framework for pharmacologic therapy across the lifespan. J Endocrinol Invest. 2025;48(12):2761-2798. doi:10.1007/s40618-025-02700-7.

118. Hocking S, Sumithran P. Individualised prescription of medications for treatment of obesity in adults. Rev Endocr Metab Disord. 2023;24(5):951-960. doi:10.1007/s11154-023-09808-2.

119. American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S145-S157.